II. Epidemiology
- Of the 38% of episodic Migraine patients in whom prophylaxis is indicated, less than half are taking prophylaxis
III. Indications: Frequent Migraine Headaches
- Headache frequency
-
Headache duration
- Prolonged Headaches >2 days with Disability
-
Headache response to Migraine Abortive Treatment
- Debilitating Headache despite acute Migraine abortive agents
- Intolerance or contraindications to acute Migraine abortive agents
- Analgesic Overuse Headaches or overuse of acute Migraine abortive agents
- Other indications
- Complicated Migraine Headache subtypes (prominent neurologic findings)
IV. Protocol
- Approach
- At each step assess prophylactic agent with a validated symptom score
- Migraine Disability Assessment
- Headache Impact Test
- Migraine Physical Function Impact Diary
- Step 1: Select a first-line agent
- Beta Blocker (Propranolol, Metoprolol or Timolol)
- Divalproex (Depakote)
- Topiramate (Topamax)
- If Menstrual Migraines, Frovatriptan 2.5 mg twice daily for 5-7 days starting 0-2 days before Menses
- Step 2: Select a different first-line agent if not effective despite maximal tolerated dose
- Step 3: Consider a Calcitonin Gene-Related Peptide Blocker (CGRP Antagonist, see below)
- Step 4: Consider combining 2 first-line agents
- Step 5: Consider a second line agent
- Amitriptyline (Elavil)
- Venlafaxine (Effexor)
- Other Beta Blockers (Atenolol, Nadolol)
- If Menstrual Migraines, Zolmitriptan 2.5 mg three times daily for 5-7 days starting 0-2 days before Menses
V. Preparations: Most Effective Agents for Migraine Prophylaxis
-
Propranolol LA: Level A Evidence
- Metoprolol and Timolol have similar efficacy to Propranolol in Migraine Prophylaxis (Level A evidence)
- First choice unless Beta Blocker contraindication
- Propranolol 80 mg orally daily
- Gradually increase over 2-3 weeks until effective dose (typically 80 mg twice daily or 160 mg daily)
- Maximum: 240 to 320 mg orally daily
- May substitute with generic Propranolol (split daily dose into 3-4 divided doses)
- Alternatives
- Metoprolol 25-50 mg at bedtime nightly, then increase by 25 mg weekly up to 50-100 mg daily
-
Amitriptyline (Elavil) or Nortriptyline (Pamelor): Level B Evidence
- Effective, but considered a second-line agent due to more adverse effects
- Effexor has similar efficacy in Migraine Prophylaxis to Tricyclic Antidepressants
- Consider in patients with comorbid Tension Headaches
- Start: 10 mg orally at bedtime
- Increase by 10 mg each week until at least 30 mg, and preferably 50-100 mg at bedtime
-
Valproic Acid and derivatives: Level A Evidence
- Teratogenic (avoid in women at risk for pregnancy)
- See description for adverse effects and monitoring
- Depakote Extended Release (ER) start 500 mg orally daily
- Increase after 1 week to 500 mg orally twice daily
- May increase in 250 mg increments if adverse effects
- Preferred Valproate form for Migraine Prophylaxis
- Other preparations
- DivalproexSodium (Depakote) 250-500 mg orally twice daily
- Valproic Acid (Depakene) 250-500 mg twice daily
-
Topiramate (Topamax): Level A Evidence
- Teratogenic (avoid in women at risk for pregnancy)
- May blunt cognitive function and cause weight loss
- Dosing
- Bedtime dosing
- Start: 12.5 to 25 mg orally at bedtime
- Increase by 12.5 to 25 mg each week, until at 100 mg at bedtime
- Alternative twice daily dosing
- Start: 12.5 to 25 mg orally at bedtime for 1 week
- Next: 25 mg orally twice daily for 1 week
- Next: 25 mg orally in AM and 50 mg orally in PM for 1 week
- Next: 50 mg orally twice daily
- Bedtime dosing
- Efficacy
- Effective prophylaxis at 100-200 mg per day
- Silberstein (2004) Arch Neurol 61:490-5 [PubMed]
- Brandes (2004) JAMA 291:965-73 [PubMed]
VI. Preparations: Calcitonin Gene-Related Peptide Blocker (CGRP Antagonist)
-
General
- Biologic Agents released in 2018 to block the CGRP vasodilator
- Expensive ($6900/year)
- Indications
- Indicated in Migraines refractory to at least two first-line Migraine Prophylaxis agents
- Indications to continue agent after 3-6 months
- Headache days per month reduced by at least 50% OR
- Significant improvement on validated Migraine Headache survey (see above)
- Preparations
- Aimovig (Erenumab)
- Autoinjector once monthly
- Ajovy (Fremanezumab)
- Three injections from prefilled syringes once every 3 months
- Emgality (Galcanezumab)
- Once monthly injection via pen
- Aimovig (Erenumab)
- Efficacy
- References
- (2018) Presc Lett 25(12): 70
VII. Preparations: Comorbidity Directed
- Neck Pain, Neuralgia, scalp Allodynia
- Frequent or prominent aura, or aura with Hemiplegia or autonomic symptoms
- Post-Traumatic Headache
- Anxiety or hyperadrenergic state
- Beta Blocker (e.g. Propranolol, Metoprolol)
- Overweight or Obesity
- Dizziness
- Seizure Disorder
-
Hypertension
- Beta Blocker (e.g. Metoprolol)
- Mental Health Conditions
- Venlafaxine (Effexor) for Major Depression or anxiety
- Divalproex (Depakote) for Bipolar Disorder
- Tricyclic Antidepressants (Amitriptyline, Nortriptyline) for Major Depression or Insomnia
VIII. Preparations: Antihypertensives
- Most effective agents - All are Beta Blockers (Level A evidence)
- Propranolol (Inderal)
- Start at 80 mg and titrate to effect up to 320 mg orally daily
- Use long acting (LA) once daily or divide two to three times daily with short acting
- Timolol
- Start at 10-15 mg orally once daily
- Increase to 20-30 mg orally daily or divided twice daily
- Metoprolol (Toprol XL, Lopressor)
- Start at 25-50 mg orally daily (succinate) or divided twice daily (tartrate)
- Titrate dose to effect up to 200 mg/day
- Propranolol (Inderal)
- Probably effective - All are Beta Blockers (Level B evidence)
- Possibly effective (Level C)
- Inadequate evidence
- Ineffective (avoid)
IX. Preparations: Nonsteroidal Antiinflammatory Drugs (NSAIDS)
- Risk of Analgesic Overuse Headache
- Probably effective (Level B)
- Naproxen
- NaproxenSodium (Anaprox) 550 mg twice daily
- Fenoprofen
- Ketoprofen
- Ibuprofen
- Possibly effective (Level C)
- Unknown Efficacy
- Ineffective
X. Preparations: Antidepressants
- Probably effective (Level B evidence)
- Amitriptyline (Elavil) 30 to 150 mg orally daily
- Venlafaxine (Effexor)
- Inadequate evidence
- Fluvoxamine
- Protriptyline
- Fluoxetine (Prozac) 20-40 mg orally daily
- Headache worsens in 30% of cases
- Steiner (1998) Cephalalgia 18:283-6 [PubMed]
- Ineffective agents (avoid)
XI. Preparations: Anticonvulsants
- Most effective agents (Level A Evidence)
- Valproic Acid (Depakote) 250 to 750 mg orally twice daily
- Topiramate (Topamax)
- Possibly effective (Level C evidence)
- Inadequate evidence
- Ineffective (avoid)
XII. Preparations: Complementary Therapy, Non-Pharmacologic and Vitamin Supplementation
- Most effective (Level A)
- Petasites hybridus (Butterbur): Petadolex 50-75 mg orally twice daily
- May reduce Migraine frequency by 50%
- GI intolerance is common (and hepatotoxicity risk)
- Lipton (2004) Neurology 63:2240-4 [PubMed]
- Petasites hybridus (Butterbur): Petadolex 50-75 mg orally twice daily
- Probably effective (Level B)
- Relaxation Training, Biofeedback, Cognitive Behavioral Therapy
- Tanacetum parthenium (Feverfew) 50 to 82 mg daily
- Vitamin B2 (Riboflavin) 400 mg orally daily
- Acupuncture
- Appears as effective as standard Migraine Prophylaxis medications
- See Acupuncture for additional studies
- Da Silva (2015) Headache 55(3): 470-3 [PubMed]
- Possibly effective (Level C)
- Coenzyme Q10 100 mg orally three times daily
- Reduces Migraines by a third
- Sandor (2005) Neurology 64:713-5 [PubMed]
- Magnesium Oxide 300 mg daily or Magnesium Dicitrate 600 mg daily
- May also assist with Migraine medication-induced Constipation
- May reduce severity and duration of Migraines
- Wang (2004) Headache 43(6):601-10 [PubMed]
- Coenzyme Q10 100 mg orally three times daily
XIII. Preparations: Miscellaneous
- Probably effective (Level B)
- N-alpha-methyl Histamine
- Dose 1-10 ng twice weekly SQ Injection
- Millan-Guerrero (2006) Can J Neurol 33: 195-99 [PubMed]
- Botulinum Toxin A injections
- Third-line option after 2-3 failed prophylactic agents
- Indicated in chronic Migraines but not episodic Migraines
- Injection sites
- FDA approved for chronic Migraines since 2010
- Best effect after 3 cycles of injection
- Silberstein (2014) J Neurol Neurosurg Psychiatry [PubMed]
- N-alpha-methyl Histamine
- Possibly effective (Level C)
- Cyproheptadine (Periactin) 4-16 mg orally daily
- Inadequate evidence
- Lithium Carbonate (Lithobid) 300 mg PO bid-tid
- Anticoagulants and antiplatelet agents
- Cyclandilate
- Coumadin
- Picotamide
- Acenocoumarol
- Ineffective (avoid)
XIV. References
- Robertson (2017) Migraine Headache Prevention, Mayo Clinical Reviews, Rochester, MN
- Jackson (1998) CMEA Internal Medicine Lecture, San Diego
- Ha (2019) Am Fam Physician 99(1): 17-24 [PubMed]
- Holland (2012) Neurology 78(17):1346-53 [PubMed]
- Modi (2006) Am Fam Physician 73:72-80 [PubMed]
- Moore (1997) Am Fam Physician 56(8):2039-48 [PubMed]
- Noble (1997) Am Fam Physician 56(9):2279-86 [PubMed]
- Parsekyan (2000) West J Med 173:341-5 [PubMed]
- Polizzotto (2002) J Fam Pract 51(2):161-7 [PubMed]
- Silberstein (2012) Neurology 78: 1337-45 [PubMed]